Abstract-The impact of diet on cardiovascular disease has become an increasingly relevant topic as ongoing epidemiological evidence continues to demonstrate clear associations with disease burden and mortality. Certain diets, such as those high in sodium and saturated fat, are associated with cardiovascular disease states, while other diets can be cardioprotective. However, there is limited knowledge on how the micro-and macronutrients within such cardioprotective diets afford their benefits. One such micronutrient is the catechin class, which are naturally occurring compounds in plant foods, such as teas, cocoa, wine, pears, and apples. Recent evidence reveals that catechins may be a key mediator in cardiovascular health via mechanisms of blood pressure reduction, flow-mediated vasodilation, and atherosclerosis attenuation. This review evaluates the current literature on the interplay between catechins and cardiovascular disease, which may have important implications for nutrition counseling and pharmaceutical drug development. Visual Overview-An online visual overview is available for this article.
I n recent years, there has been a growing interest in the relationship between diet and cardiovascular health. Certain diets, such as those high in sodium and saturated fat, are known to be associated with cardiovascular disease states, such as hypertension and atherosclerosis. 1 Current guidelines, including those endorsed by the American Health Association, emphasize heart-healthy diets such as the DASH diet (Dietary Approaches to Stop Hypertension) and the Mediterranean diet, which both incorporate ample consumption of fruits, vegetables, low-fat dairy and lean meats. [2] [3] [4] [5] These diets are beneficial for both disease and mortality reduction. [6] [7] [8] The Mediterranean diet, for example, is associated with a 50% lower incidence of all-cause mortality and cardiovascular-specific mortality. 9 However, there is limited literature that identifies how individual micro-and macronutrients within these diets contribute to disease and mortality reduction. One such micronutrient is the catechin class, which is a type of flavanoid found in common plant foods, such as legumes, teas, cocoa, grapes, apples, pears, and several other fruit. 10 Epidemiological studies have shown that populations consuming high quantities of catechins have a decreased incidence of coronary artery disease. 11 The cardioprotective effects of catechins are manifold and include reductions in systemic blood pressure, atherosclerosis, platelet activation, and thrombus formation. This review highlights the current literature on the relationship between catechins and cardiovascular health, which may prove to have implications for nutrition counseling, as well as pharmaceutical development.
The Catechin Class
The catechins are a class of flavanoids found naturally in plant-based foods, such as cocoa, tea, fruits, and legumes. 12 Chocolate and apples contain the largest amount of procyanins, which are oligomeric compounds formed by catechins. 13, 14 After consumption, catechins are absorbed in the small intestine and thereafter undergo end-product modification, including glucoronidation, sulphation, and methylation, in the liver. 15 The specific catechins subtypes most commonly cited as cardioprotective are (+)-catechin and (−)-epicatechin. 16 
Systemic Blood Pressure
There is a substantial body of evidence demonstrating the beneficial effects of catechin consumption on blood pressure. Overall, it seems that human consumption of catechins, particularly via cocoa, reduces blood pressure and improves flow-mediated vasodilation (FMD). 17 A recent Cochrane Review meta-analysis of 20 randomized controlled trials including 856 subjects found that cocoa consumption was associated with a mean reduction in systolic blood pressure by 2.77 mm Hg (P=0.005) and diastolic blood pressure by 2.20 mm Hg (P=0.006). 18 In another meta-analysis by Ellinger et al, 19 a nonlinear regression model incorporating data from 16 randomized controlled trials and 391 subjects revealed that there is an inverse relationship between catechin consumption and systemic blood pressure. Namely, at roughly 25 mg of epicatechin, which is the amount that can be found in 25 to 30 g of commercial cocoa, there is a reduction in systolic blood pressure by roughly 4.1 mm Hg (95% confidence interval [CI], −4.6 to −3.6 mm Hg) and diastolic blood pressure by roughly 2 mm Hg (95% CI, −2.4 to −1.5 mm Hg). 19 One of the largest single center studies was that of Buijsse et al, 20 which followed blood pressure, cardiovascular disease, and chocolate consumption in a 19 357 German male cohort over 8 years. Those who consumed the top quartile of chocolate had a lower mean systolic blood pressure by 1.0 mm Hg (95% CI, 1.6-0.4 mm Hg) and a lower mean diastolic blood pressure by 0.9 mm Hg (95% CI, 1.3-0.5 mm Hg) compared with the bottom quartile of chocolate consumers. 20 Further, after controlling for cardiometabolic variables, the relative risk of myocardial infarction and stroke in the top quartile of chocolate consumers versus the bottom quartile was 0.61 (95% CI, 0.44-0.87; P=0.014), suggesting significant differences in cardiovascular outcomes based on chocolate consumption. Other smaller trials have surfaced supporting the inverse relationship between catechin consumption and systemic blood pressure reduction. Table 1 summarizes these trials. Taubert et al 21 found that in 13 subjects with normal blood pressure, consumption of chocolate for 14 days was associated with a 5.1 mm Hg (P<0.001) mean decrease in systolic blood pressure and a 1.6 mm Hg (P=0.002) mean decrease in diastolic blood pressure. Similarly, Grassi et al 25 found that in 19 hypertensive subjects randomly assigned to 15 days of flavanol-rich or flavanol-free chocolate, those who consumed flavanol-rich chocolate experienced a significant reduction in systolic and diastolic blood pressure by 3.82 and 3.92 mm Hg, respectively. Although these studies represent relatively small populations, they reflect a general trend in blood pressure reduction with consumption of foods containing sufficient amounts of catechins. Other studies, however, have demonstrated that catechins may not decrease blood pressure, but rather have a neutral effect. Dower et al 31 randomized 37 healthy patients to either 100 mg/d of (−)-epicatechin or placebo for 4 weeks and found no difference in systemic blood pressure. Similarly, in a study that involved 40 hypertensive subjects randomized to either a flavanol-rich drink (roughly 900 mg flavanol/d) or placebo for 2 weeks, there was no significant difference found in blood pressure. 27 One significant criticism of the current literature is that the majority of studies do not report current antihypertensive medication use or specifically exclude patients taking antihypertensive medications. As such, it remains unclear if there are potential interactions between antihypertensive medications and catechin consumption. Additionally, a major concern with the current evidence is the lack of control for alternative compounds found within catechin-rich foods, which may affect blood pressure. Finally, an increased consumption of catechin-rich foods, particularly chocolate, may be accompanied by increased sugar intake, which may worsen glycemic control in diabetics. Commercialized chocolate also contains high amounts of saturated fat, which has previously been associated, albeit controversially, with increased cardiovascular mortality. 34 
FMD, Peripheral Vasodilation, and Coronary Vasodilation
FMD, or the endothelial-driven vasodilatory response to transient ischemia, also seems to be influenced by catechin consumption (Table 2) . Nitric oxide-mediated vasodilatation is a normal physiological response in healthy subjects but can become diminished or dampened in those with coronary artery disease or atherosclerosis. 38 Impaired FMD has also been identified as an independent predictor of future cardiovascular events. 39 Balzer et al 36 found that consumption of flavanol-enriched cocoa is associated with a dosedependent increase in FMD. Ten subjects who consumed increasing amounts of flavanol concentrations, which contained mostly (−)-epicatechin, had a significant increase in FMD ≤6 hours after ingestion. Forty-one subjects were also randomized to drink either a control concentration or a high-dose flavanol (963 mg/d) concentration, and at the 30-day mark, those who consumed high-dose flavanol concentrations continued to have a sustained dose-dependent response in FMD, suggesting the absence of attenuation over time. Schroeter et al 40 demonstrated that subjects who consumed pure (−)-epicatechin or flavanol-rich cocoa experienced similar changes in FMD, suggesting the key role of (−)-epicatechin in particular. Finally, Engler et al 35 found similar results in a cohort of 21 patients randomized to high or low flavonoid concentrations. The mechanisms involved in catechin-induced FMD are indeed mediated by novel nitric oxide production. Numerous rat and human models have previously validated this relationship using in vivo nitric oxide assays. [41] [42] [43] Further, in a study by Fisher et al 44 involving 27 human subjects, peripheral vasodilation after consumption of flavanol-rich cocoa was reversed with a nitric oxide synthase inhibitor, confirming that the mechanism of flavanol-induced vasodilation is nitric oxide dependent. In this study, FMD was assessed via pulse wave amplitudes obtained using a plethysmographic device on the index finger of subjects both before and after 5 minutes of radial artery occlusion. After 4 days of flavanol-rich cocoa consumption containing roughly 0.070 mg/g epicatechin and 0.082 mg/g catechin, pulse wave amplitudes had increased by 29% (7.3±0.7 to 9.4±1.0 μL; P=0.01). Further, on the fifth day when patients were given an additional dose of cocoa followed by an infusion with L-arginine methyl ester, a potent nitric oxide synthase inhibitor, pulse wave amplitudes decreased by 36% (12.5±2.5 bμL after cocoa to 8.0±0.7 μL after L-arginine methyl ester; P=0.004). Another study demonstrated that the effects of high flavanol cocoa on FMD are preserved with chronic administration. 37 Davison et al 37 The role of increasing FMD may also prove to be beneficial in disease states subject to low-flow ischemia, such as peripheral artery disease. In a small study by Loffredo et al, 45 20 patients with confirmed peripheral artery disease were randomized to receive either 40 g of dark chocolate or 40 g of milk chocolate. Those who received dark chocolate, which was associated with significantly higher serum epicatechin levels, experienced a significant increase in maximal walking distance (+11%; P<0.001), maximal walking time (+15%; P<0.001), and serum nitric oxide (+57%; P<0.001). However, those who received milk chocolate did not experience any significant changes in these parameters.
Furthermore, the question of whether catechin consumption has any effect on coronary vasodilation is of particular importance in the management of coronary artery disease. Flammer et al 46 found that in heart-transplant patients who underwent routine coronary angiograms, ingestion of 40 g of flavanol-rich chocolate compared with control chocolate resulted in a significant increase in coronary artery diameter (2.36±0.51 to 2.51±0.59 mm; P<0.01). In this study, subjects underwent coronary angiograms both before and 2 hours after consumption of either 40 g of dark chocolate (0.27 mg/g catechin and 0.9 mg/g epicatechin) or control chocolate (flavanoid free). Each angiogram included imaging at rest and after immersion of the subject's hand in ice water for 2 minutes. Interestingly, after cold-water immersion, subjects who consumed cocoa experienced coronary vasodilation (+4.5%±11.4%), whereas controls experienced coronary vasoconstriction (−4.3%±11.7%; P=0.018). This finding may have implications in cases of coronary vasospasm; however, as only acute ingestion of cocoa was studied, it is unclear if the same effects can be extrapolated to chronic consumption. Some studies, however, have demonstrated a neutral effect of catechins on FMD. In a study involving 40 hypertensive subjects randomized to either a flavanol-rich drink (roughly 900 mg flavanol/d) or placebo for 2 weeks, there was no significant difference in FMD found.
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Atherosclerosis
The majority of studies assessing the effect of catechin consumption on atherosclerosis are based on animal models and epidemiological studies. One of the largest studies is a prospective cohort study that surveyed 34 492 postmenopausal Most studies were compared with either placebo or low-flavanol controls. BMI indicates body mass index; and BP, blood pressure.
women between ages 55 and 69 over the span of 13 years and showed that there is an inverse relationship between consumption of foods rich in (+)-catechins and (−)-epicatechins and deaths from coronary artery disease. 16 Even after multivariate adjustment for diabetes mellitus, body mass index, blood pressure, physical activity, pack-years of smoking, estrogen replacement therapy, and micronutrient consumption, including whole grains and polyunsaturated fatty acids, the inverse relationship remained. Those who consumed the highest quantities of (+)-catechins and (−)-epicatechins had a 0.76 relative risk of death from coronary artery disease. Reis et al 47 studied a smaller cohort of 5115 subjects over 20 years and found that tea consumption was associated with a nonsignificant inverse relationship with coronary artery calcification scores. Janszky et al 48 found that in a cohort of 1169 subjects followed for 8 years after their first myocardial infarction, those who had the highest frequency of chocolate consumption had a strong inverse association with subsequent cardiovascular-specific mortality. In fact, when compared with those who never consumed chocolate, those who consumed chocolate 2 or more times per week had a multivariable-adjusted hazard ratio for cardiac mortality of 0.34 (95% CI, 0.17-0.70; P=0.01).
Rodent models have offered the majority of evidence on the mechanisms by which catechins may mitigate atherosclerosis. Hayek et al 49 found that in 40 apolipoprotein E (ApoE)-deficient mice who were fed catechin-rich water at 50 μg/d versus placebo for 6 weeks, atherosclerotic aortic arch lesion areas were 39% smaller (P<0.05) in the catechin group compared with the placebo group. Further, catechin-treated mice had a 31% reduction in low-density lipoprotein cellular uptake and a reduced susceptibility to oxidation. In another rodent study, ApoE-deficient mice were fed an atherogenic diet with or without catechinrich tea extract, which contained 584 mg/g (−)-epigallocetechin-gallate, 117 mg/g (−)-epigallocatechin, 66 mg/g (−)-epicatechin, 16 mg/g (+)-gallocatechingallate, and 5 mg/g (−)-epicatechingallate. Over a 14-week period, ApoE-deficient mice consumed an average of 3.2 mg/d of tea extract and experienced a significant attenuation in the amount of atherosclerosis in their entire aortic area by 23% compared with controls (P<0.01). Further, tea-treated mice had reductions in their aortic weight by 23% (P<0.001) and cholesterol content by 27% (P=0.01) compared with the controls. 50 These results were further expanded on by Morrison et al, 51 who assessed the effect of pure (−)-epicatechin extracts on female-only ApoE2-leiden mice. In the study, the mice were fed a Western-type diet with supplemental 1% cholesterol for 4 weeks and then given either (−)-epicatechin or control for 16 additional weeks. Both groups were continued on a high-cholesterol diet. After 20 weeks, epicatechin-treated mice consumed roughly 110±11 mg/kg body weight of epicatechin per day and experienced a 27% attenuation in atherosclerotic lesion area compared with control mice not supplemented with epicatechin. The mechanism of atherosclerotic attenuation did not seem to involve prevention of dyslipidemia because epicatechintreated mice had no significant differences in total cholesterol levels of lipoprotein profiles. 51 In another study by Auclair et al, 52 male apoE-deficient mice who were fed a high-catechin diet for 6 weeks at doses of 0.02% of total meal, which equates to roughly 100 mg/d in human intake, had a 32% reduction of the mean atherosclerotic lesion area as compared with a control group not supplemented with catechins (P<0.01). Further, catechin-treated mice demonstrated downregulation of numerous atherogenic genes, including the gene that encodes for lipoprotein lipase. Lipoprotein lipase is a rate-limiting enzyme that breaks down circulating triglycerides from chylomicrons and very low-density lipoproteins into free fatty acids and low-density lipoproteins. Other genes involved in the direct cascade of atherogenesis, such as SCARA5, FABP4, CD34, and Selpl, were also significantly downregulated. These studies highlight the inverse relationship between catechin consumptions and both in situ atherosclerosis and coronary artery events.
Antiplatelet and Antithrombotic Effects
Catechin consumption also seems to have an inverse relationship with platelet aggregation and subsequent thrombus formation, although this relationship is less defined. Pearson et al examined the effect of cocoa on ex vivo platelet function in 16 healthy adults and found that flavanol-rich cocoa effectively inhibited epinephrine-stimulated platelet activation. 53 In the study, subjects consumed 81 mg aspirin, aspirin plus cocoa (containing 897 mg epicatechin), and cocoa alone on 3 different crossover days, separated by 14 days when aspirin was consumed. Platelet activation was assessed 2 hours and 6 hours after consumption using ex vivo assays for PAC-1 (procaspace-activating compound), which binds to GPIIb/IIIa, and P-selection, a marker for activated platelets. Cocoa consumption significantly reduced GpIIb/IIIa expression 2 hours after consumption (P=0.005); however, it had no effect on P-selection expression. Platelet function was also assessed using an analyzer that measured collagen-epinephrine and collagen-ADP platelet plug formation under shear stress. The authors found that cocoa significantly reduced both CEPI (collagen and epinephrine)-stimulated closure times at 6 hours and CADP (collagen and adenosine disphosphate)-stimulated closure times at 2 hours. Overall, these results suggest a significant reduction in platelet activation and function after catechin consumption. However, other studies have shown less promising results on the relationship between catechin consumption and platelet aggregation. Duffy et al 54 analyzed platelet aggregation studies in 49 subjects with confirmed coronary artery disease who consumed either 900 mL of black tea or water daily. Tea concentration contained roughly 13 mg/dL of total catechins. After 8 weeks, there was no significant difference in ex vivo platelet aggregation between the 2 groups using either ADP (adenosine disphosphate)-induced or TRAP (thrombin receptor agonist peptide)-induced assays. However, notably in this study, all subjects were taking high dose aspirin as part of their coronary artery disease regimen, so it is not entirely clear if tea consumption would have demonstrated an effect in the absence of aspirin.
Conclusions
There is a large body of evidence that supports the numerous cardioprotective effects of catechin consumption, namely, a reduction in systemic blood pressure, increase in FMD, and an attenuation of atherosclerosis, platelet activation, and thrombosis formation. Blood pressure reduction is the most validated association, particularly with use of dark chocolate at 100 g daily. These findings suggest that catechins may be one of the key mediators of cardiovascular health in previously established heart-healthy diets, such as the DASH diet or the Mediterranean diet. Overall, there does not seem to be significant adverse effects to excess catechin consumption aside from an overabundance of concomitant macronutrients in catechin-rich foods, such as the sugar or saturated fat content found in chocolate. Nonetheless, many questions remain unanswered regarding the effects of catechins. It is unclear whether trials that exhibited statistical significance will translate to clinical significance with respect to reducing long-term cardiovascular outcomes. Further, a chief criticism of the current literature is that catechin-containing food is frequently used as a surrogate for catechins, which may be confounded by the presence of alternative components within the food items. Future efforts should focus on placebo-controlled trials involving pure catechin derivatives and a patient population with preexisting cardiovascular disease. At present, several larger trials are currently underway, such as the COCOA-BP trial (Chocolate Consumption And Blood Pressure) and the FLAVASCULAR study (The Effects of Apple Derived Flavanols on Cardiovascular Disease Risk), which both seek to evaluate the effect of catechin-rich food on systemic blood pressure. 55, 56 The potential implications of such research would be particularly meaningful for future pharmaceutical drug development should larger scale trials corroborate the current medical literature.
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